Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)

Shimizu, Junichi; Masago, Katsuhiro; Saito, Haruhiro; Nishino, Kazumi; Kurata, Takayasu; Itoh, Yohji; Yoshimura, Yoko; Yabuki, Yutaka; Dosaka-Akita, Hirotoshi

Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)

Shimizu, Junichi; Masago, Katsuhiro; Saito, Haruhiro et al.

Therapeutic advances in medical oncology, 2020, 12, UNSP 1758835920904522

Permalink : https://hdl.handle.net/2115/77498

このアイテムのアクセス数:596件（2026-08-13 21:22 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1177/1758835920904522			18

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/77498
タイトル	Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)
著者	Shimizu, Junichi ; Masago, Katsuhiro ; Saito, Haruhiro ; Nishino, Kazumi ; Kurata, Takayasu ; Itoh, Yohji ; Yoshimura, Yoko ; Yabuki, Yutaka ; Dosaka-Akita, Hirotoshi
著者名 Shimizu, Junichi
e-Rad_Researcher 80338160 著者名 Masago, Katsuhiro
著者名 Saito, Haruhiro
著者名 Nishino, Kazumi
e-Rad_Researcher 40340781 著者名 Kurata, Takayasu
著者名 Itoh, Yohji
著者名 Yoshimura, Yoko
著者名 Yabuki, Yutaka
e-Rad_Researcher 70222528 著者名 Dosaka-Akita, Hirotoshi
言語	英語
キーワード	anaplastic lymphoma kinase
	epidermal growth factor receptor
	programmed death-ligand 1
	ROS1
発行日	2020-02
出版者	SAGE Publications
収録物名	Therapeutic advances in medical oncology
巻(号)	12
ページ	UNSP 1758835920904522
抄録	Background: Molecular diagnostic testing is necessary to guide optimal first-line treatment. The number of patients who receive first-line treatment based on biomarker analysis in Japan is unknown. We aimed to determine the proportion of nonsquamous non-small cell lung cancer (NSCLC) patients for whom first-line treatment was selected based on biomarker testing. Methods: This retrospective, multicenter, observational study registered patients aged > 20 years with locally advanced or metastatic nonsquamous NSCLC who started first-line treatment between August and December 2017 in Japan. Data were collected from medical records between January and May 2018. The primary endpoint was the proportion of patients with confirmed biomarker status for first-line treatment decision. Results: Among 202 patients enrolled from 11 centers, 161 (79.7%; 95% confidence interval, 74.2-85.2%) had confirmed biomarker status. The testing rate was highest for epidermal growth factor receptor (EGFR; 97.5%), followed by anaplastic lymphoma kinase (ALK; 88.1%), programmed death ligand-1 (PD-L1; 87.1%), and ROS1 (67.3%). For first-line treatment, 70/75 patients with EGFR-positive tumors were administered an EGFR-TKI; 14/15 patients with ALK-positive tumors received an ALK inhibitor; 2/2 patients with ROS1-positive tumors received a ROS1 inhibitor; and 29/36 driver mutation-negative patients with a PD-L1 tumor proportion score > 50% were administered an anti-PD-1 monoclonal antibody. Median times from confirmed diagnosis date to first-line treatment initiation, and from first biomarker test order to last biomarker test result were 19 and 11 days, respectively. Conclusions: The proportion of nonsquamous NSCLC patients with confirmed biomarker status for first-line treatment was considered insufficient and in need of improvement.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	1758-8340
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1177/1758835920904522